Insights From Technical Analysis
Pacific Edge (ASX: PEB): Testing Critical Resistance, Breakout or Reversal Ahead?
Pacific Edge (ASX: PEB) tests critical resistance near 0.240 after surging on draft Medicare coverage, a 75% increase in reimbursement rates, and a NZ$25.4 million capital raise. Strong volume supports the rally, but RSI near 70 warns of potential pullback risk.
Hawk Resources (ASX: HWK): Is the Volume Surge Pointing to a Fresh Breakout Attempt?
Hawk Resources is an early-stage explorer targeting high-grade copper-gold in Utah and lithium in Brazil, with emerging exposure to rare earths. Recent trading was driven by its Olympus scandium deal, a A$5.87A$5.87 million raising, and renewed momentum at Cactus.
Lumos Diagnostics (ASX: LDX) Shares Keep Sliding Despite Last Year’s Rally
Lumos Diagnostics shares have dropped sharply after last year’s rally, with weak technical signals and dilution concerns weighing on sentiment. Despite long-term optimism around FebriDx and US commercialisation, investors remain cautious due to slow revenue growth and ongoing funding pressures.
Why Megaport (ASX: MP1) Shares Just Skyrocketed More Than 35%?
Megaport (ASX: MP1) shares surged over 35% after the company secured AI infrastructure contracts worth A$254 million through Latitude.sh, strengthening its position in the booming AI compute and cloud connectivity market.
Can Develop Global (ASX: DVP) Sustain Its Breakout Toward New Highs?
Develop Global (ASX: DVP) is gaining momentum as Woodlawn reaches steady-state production, Sulphur Springs economics improve, and mining services expand. Supported by strong copper and zinc markets, the company’s breakout reflects operational execution, contract growth, and multiple upcoming catalysts.
Is Arafura Rare Earths (ASX: ARU) Ready to Make Its Next Move Higher?
Arafura Rare Earths is advancing its Nolans project as a major non-China NdPr supplier, supported by strategic offtakes, sector tailwinds, and improving technical momentum, though investors still face key risks including funding, execution delays, and rare earth price volatility.